Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930706 | 0.84 | CTSS (0.35) | CTSSCTSKMAPK1GAAUSP2 | |
| SCHEMBL20078588 | 0.83 | CTSS (0.40) | CTSSCTSKMAPK1GAAALDH1A1 | |
| SCHEMBL9972470 | 0.81 | CTSS (0.44) | CTSSCTSKMAPK1GAAALDH1A1 | |
| SCHEMBL1983218 | 0.81 | MAPK1 (0.54) | CTSSCTSKMAPK1ALDH1A1USP2 | |
| SCHEMBL5990092 | 0.81 | CTSS (0.44) | CTSSCTSKMAPK1GAAALDH1A1 | |
| SCHEMBL12598695 | 0.81 | CTSK (0.44) | CTSSCTSKCA2 | |
| SCHEMBL3265338 | 0.81 | CTSS (0.44) | CTSSCTSKMAPK1GAAALDH1A1 | |
| SCHEMBL28501721 | 0.81 | ALDH1A1 (0.56) | GAAALDH1A1L3MBTL1USP2CYP2C9 | |
| SCHEMBL1983219 | 0.81 | MAPK1 (0.54) | CTSSCTSKMAPK1ALDH1A1USP2 | |
| SCHEMBL7878136 | 0.79 | CTSS (0.43) | CTSSCTSKMAPK1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885MAPK1 2093/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885MAPK1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.